

**2015 DRAFTING REQUEST**

**Assembly Amendment (AA-AB367)**

Received: **10/12/2015** Received By: **tdodge**  
For: **John Nygren (608) 266-2343** Same as LRB:  
May Contact: By/Representing: **Jenny**  
Subject: **Mental Health - AODA** Drafter: **tdodge**  
Addl. Drafters:  
Extra Copies:

Submit via email: **YES**  
Requester's email: **Rep.Nygren@legis.wisconsin.gov**  
Carbon copy (CC) to: **tamara.dodge@legis.wisconsin.gov**

---

**Pre Topic:**

No specific pre topic given

---

**Topic:**

Eliminate requirement to review prescription drug monitoring database

---

**Instructions:**

See attached

---

**Drafting History:**

<u>Vers.</u>	<u>Drafted</u>	<u>Reviewed</u>	<u>Proofed</u>	<u>Submitted</u>	<u>Jacketed</u>	<u>Required</u>
/?	tdodge 10/19/2015		_____			
/P1	tdodge 10/20/2015	wjackson 10/20/2015	_____	mbarman 10/19/2015		
/1			_____	lparisi 10/20/2015	lparisi 10/20/2015	

FE Sent For:

<END>



State of Wisconsin  
2015 - 2016 LEGISLATURE

LRBa0866(?)  
TJD: *Jld*

In: 10/19

*Due today  
if possible*

**PRELIMINARY DRAFT - NOT READY FOR INTRODUCTION**  
**ASSEMBLY AMENDMENT,**  
**TO ASSEMBLY BILL 367**

1 At the locations indicated, amend the bill as follows:

2 **1.** Page 2, line 1: delete the material beginning with "**programs;**" and ending  
3 with "(a)" on line 2 and substitute "**programs. (1)**". ✓

4 **2.** Page 2, line 16: delete "(b)" and substitute "**(2)**". ✓

5 **3.** Page 2, line 16: delete "par. (a)" and substitute "sub. (1)". ✓

6 **4.** Page 2, line 19: delete lines 19 to 22. ✓

7 **(END)**

*move*

*#. Page 2, line 4: delete "1." and substitute "(a)".  
#. Page 2, line 6: delete "2." and substitute  
"(b)".  
#. Page 2, line 8: delete "3." and substitute  
"(c)".  
#. Page 2, line 10: delete "4." and substitute "(d)".  
#. Page 2, line 11: delete "5." and substitute "(e)".  
#. Page 2, line 13: delete "6." and substitute "(f)".  
#. Page 2, line 15: delete "7." and substitute "(g)".*

## **Dodge, Tamara**

---

**From:** Malcore, Jennifer  
**Sent:** Tuesday, October 20, 2015 9:45 AM  
**To:** Dodge, Tamara  
**Cc:** jfitzgerald@paladincg.com  
**Subject:** LRB 866/ Assembly Bill

Tami,

Could you please add this to the reporting requirements?

- The number of individual on each of the three forms of Medication Assisted Treatment (MAT) (methadone, buprenorphine containing products, and oral or extended-release injectable naltrexone) approved by the Food and Drug Administration (FDA).
- The number of individuals that engage in an aftercare program and the number that are treated with antagonist medication (oral or extended-release injectable naltrexone) as a part of relapse prevention.

Thank you,

Jenny

***Jennifer Malcore***

Office of State Representative John Nygren  
Co-Chair , Joint Committee on Finance  
89<sup>th</sup> Assembly District  
309 East, State Capitol  
608.267.2371

## **Dodge, Tamara**

---

**From:** Malcore, Jennifer  
**Sent:** Tuesday, October 20, 2015 9:46 AM  
**To:** Dodge, Tamara  
**Subject:** Sorry, that was LRB 1570

Tami,

Could you please add this to the reporting requirements?

- The number of individual on each of the three forms of Medication Assisted Treatment (MAT) (methadone, buprenorphine containing products, and oral or extended-release injectable naltrexone) approved by the Food and Drug Administration (FDA).
- The number of individuals that engage in an aftercare program and the number that are treated with antagonist medication (oral or extended-release injectable naltrexone) as a part of relapse prevention.

Thank you,

Jenny

***Jennifer Malcore***

Office of State Representative John Nygren  
Co-Chair , Joint Committee on Finance  
89<sup>th</sup> Assembly District  
309 East, State Capitol  
608.267.2371



State of Wisconsin  
2015 - 2016 LEGISLATURE

LRBa0866(P1)  
TJD:jld  
e /  
TWLj

In: 10/20

Due Today  
Tues. 10/20

~~PRELIMINARY DRAFT - NOT READY FOR INTRODUCTION~~  
**ASSEMBLY AMENDMENT ,  
TO ASSEMBLY BILL 367**

- 1 At the locations indicated, amend the bill as follows:
- 2 **1.** Page 2, line 1: delete the material beginning with **“programs;”** and ending
- 3 with **“(a)”** on line 2 and substitute **“programs. (1)”**.
- 4 **2.** Page 2, line 4: delete **“1.”** and substitute **“(a)”**.
- 5 **3.** Page 2, line 6: delete **“2.”** and substitute **“(b)”**.
- 6 **4.** Page 2, line 8: delete **“3.”** and substitute **“(c)”**.
- 7 **5.** Page 2, line 10: delete **“4.”** and substitute **“(d)”**.
- 8 **6.** Page 2, line 11: delete **“5.”** and substitute **“(e)”**.
- 9 **7.** Page 2, line 13: delete **“6.”** and substitute **“(f)”**.
- 10 **8.** Page 2, line 15: delete **“7.”** and substitute **“(g)”**.
- 11 **9.** Page 2, line 16: delete **“(b)”** and substitute **“(2)”**.

Insert 1-10



2015-2016 DRAFTING INSERT  
FROM THE  
LEGISLATIVE REFERENCE BUREAU

LRBa0866/lins  
TJD:...

1 INSERT 1-10

2 1. Page 2, line 14: after that line insert:

3 “(g) The number of individuals in the treatment program on each of the three  
4 forms of medication<sup>⊖</sup> assisted treatment, specifically methadone, buprenorphine<sup>⊖</sup>  
5 containing products, and oral or extended-release injectable naltrexone, that are  
6 approved by the federal food and drug administration.

7 (h) The number of individuals<sup>⊖</sup> <sup>who</sup> engage in a program of aftercare and the  
8 number of individuals who are treated with antagonist medication, such as oral or  
9 extended-release injectable naltrexone, as part of relapse prevention.” ✓

10 END INSERT 1-10